Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barter

Showing results (341-350 of 390) with videos related to

Pageof 39
Sort By:
Journal of the American College of Cardiology|May 12, 2012
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control studyRoeland Huijgen, S Matthijs Boekholdt, Benoit J Arsenault, et al.
Annals of the Rheumatic Diseases|February 9, 2008
Differential Toll-like receptor-dependent collagenase expression in chondrocytesQ Zhang, W Hui, G J Litherland, et al.
Journal of the American College of Cardiology|March 14, 2009
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetesSanjay Patel, Brian G Drew, Shirley Nakhla, et al.
Diabetologia|May 20, 2016
In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetesBlake J Cochran, William J Ryder, Arvind Parmar, et al.
Metabolism: Clinical and Experimental|November 20, 2018
High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)Kwok Leung Ong, Nicholas Hui, Andrzej S Januszewski, et al.
Diabetologia|June 10, 2015
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
European Heart Journal|May 7, 2013
Factors underlying regression of coronary atheroma with potent statin therapyRishi Puri, Steven E Nissen, Christie M Ballantyne, et al.
European Heart Journal. Cardiovascular Imaging|January 23, 2014
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURNRishi Puri, Peter Libby, Steven E Nissen, et al.
Diabetes Care|September 6, 2014
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURNBrian Stegman, Rishi Puri, Leslie Cho, et al.
JAMA Cardiology|October 27, 2017
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical TrialGregory G Schwartz, Christie M Ballantyne, Philip J Barter, et al.
Pageof 39

Showing results (341-350 of 390) with videos related to

Sort By:
Pageof 39
Journal of the American College of Cardiology|May 12, 2012
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control studyRoeland Huijgen, S Matthijs Boekholdt, Benoit J Arsenault, et al.
Annals of the Rheumatic Diseases|February 9, 2008
Differential Toll-like receptor-dependent collagenase expression in chondrocytesQ Zhang, W Hui, G J Litherland, et al.
Journal of the American College of Cardiology|March 14, 2009
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetesSanjay Patel, Brian G Drew, Shirley Nakhla, et al.
Diabetologia|May 20, 2016
In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetesBlake J Cochran, William J Ryder, Arvind Parmar, et al.
Metabolism: Clinical and Experimental|November 20, 2018
High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)Kwok Leung Ong, Nicholas Hui, Andrzej S Januszewski, et al.
Diabetologia|June 10, 2015
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
European Heart Journal|May 7, 2013
Factors underlying regression of coronary atheroma with potent statin therapyRishi Puri, Steven E Nissen, Christie M Ballantyne, et al.
European Heart Journal. Cardiovascular Imaging|January 23, 2014
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURNRishi Puri, Peter Libby, Steven E Nissen, et al.
Diabetes Care|September 6, 2014
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURNBrian Stegman, Rishi Puri, Leslie Cho, et al.
JAMA Cardiology|October 27, 2017
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical TrialGregory G Schwartz, Christie M Ballantyne, Philip J Barter, et al.
Pageof 39